PURPOSE: To produce an antiarteriosclerotic agent which comprises a menatetrenone derivative typified by vitamin K2 and is efficacious for arteriosclerosis and has the hypocholesteremic action in serum with high safety.

CONSTITUTION: This antiarteriosclerotic agent contains a menatetrenone derivative of the formula (the dotted line means a single or double bond) as an active ingredient. As arteriosclerosis, are cited coronary arteriosclerosis, abdominal aorta sclerosis, arteriosclerosis obliterans, renal arteriosclerosis, carotid arteriosclerosis, opthalmic arteriosclerosis and cerebral arteriosclerosis. Examples of menatetrenone derivatives are 2-methyl-3[(2E,6E,10E)-3,7,11,15- tetramethyl-2,6,10,14-hexadeca-tetraenyl]naphthoquinone and 2-methyl-3-[(2 E)-3,7,11,15-tetra-methyl-2-hexadecaenyl]naphthoquinone. The ctlinical dose of the menatetrenone derivative is 1-2,000 mg/day/adult, which is given orally, intravenously, intramuscularly, rectally or percutaneously.